Sign in

You're signed outSign in or to get full access.

LC

LadRx Corp (LADX)·Q3 2017 Earnings Summary

Executive Summary

  • Quarter marked by strategic pivot: CytRx licensed global rights to aldoxorubicin to NantCell (Patrick Soon‑Shiong), received a $13M equity investment at a ~92% premium, and is eligible for up to $343M in milestones plus tiered royalties, while refocusing internally on its LADR drug‑conjugate platform .
  • Financially, Q3 net loss narrowed sharply to $5.1M from $12.2M YoY, aided by a $3.8M non‑cash gain on warrant liabilities; R&D fell ~47% YoY as aldoxorubicin costs rolled off post‑deal .
  • Balance sheet reset: cash was $46.0M, deferred revenue booked at $6.9M, and the company paid $10M on its term loan during the quarter; a 1‑for‑6 reverse split took effect Nov 1 to support continued Nasdaq listing .
  • Operating focus: >75 LADR conjugates tested year‑to‑date; four leads selected; next LADR clinical candidate targeted for nomination in Q1’18 with first IND in 2018; development and regulatory functions outsourced to Hurley Consulting to reduce fixed costs .

What Went Well and What Went Wrong

What Went Well

  • Strategic monetization of aldoxorubicin: exclusive global license to NantCell with $13M equity at $6.60 split‑adjusted (≈92% premium), up to $343M in milestones, and double‑digit royalties (STS) positions CytRx for non‑dilutive optionality on the asset .
  • Cost discipline and P&L improvement: R&D down ~47% YoY; net loss shrank to $5.1M as non‑cash warrant revaluation swung to a $3.8M gain, offsetting opex .
  • Pipeline progression and operating model shift: >75 LADR conjugates tested YTD; four leads selected; outsourcing dev/regulatory to Hurley “streamline[s] fixed expenses” and provides flexible expertise .

Quote: “The third quarter of 2017 was transformative for CytRx,” highlighting the NantCell transaction and LADR focus .

What Went Wrong

  • Still pre‑revenue: no product revenue recognized; YTD license revenue only $100k, with heavy reliance on financing and milestone optionality .
  • G&A ticked up YoY: Q3 G&A rose to $3.4M from $2.8M YoY; interest expense stayed near ~$0.83M for the quarter, reflecting debt burden .
  • Near‑term cash use and debt: cash fell to $46.0M with $10M loan payments; current portion of term loan rose to $11.05M; warrants and Nasdaq compliance remained considerations despite the reverse split .

Financial Results

Income statement and cash metrics

MetricQ1 2017Q2 2017Q3 2017
License Revenue ($)$0 $0 $0
R&D Expense ($)$6,772,582 $6,167,074 $4,755,191
G&A Expense ($)$2,979,057 $3,137,008 $3,418,808
Loss before other income (loss) ($)$(9,751,639) $(9,304,082) $(8,173,999)
Interest Expense ($)$(1,322,715) $(848,395) $(828,120)
Gain (Loss) on Warrant Liabilities ($)$(32,119) $(4,303,945) $3,763,855
Net Loss ($)$(11,044,104) $(14,358,297) $(5,124,419)
Diluted EPS ($)$(0.10) $(0.10) $(0.19)
Cash & Equivalents ($)$48,003,315 $54,972,846 $45,995,642

YoY snapshot (Q3)

MetricQ3 2016Q3 2017
R&D Expense ($)$8,927,037 $4,755,191
G&A Expense ($)$2,771,732 $3,418,808
Net Loss ($)$(12,175,450) $(5,124,419)
Diluted EPS ($)$(0.80) $(0.19)

Notes:

  • Deferred revenue recorded at $6,924,353 (current) on Q3 balance sheet, reflecting licensing arrangements .
  • Debt service actions: $10M payments made on term loan in Q3; term loan current portion at $11,052,705 .

(No segments or product KPIs reported; company is pre‑commercial.)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
LADR: next clinical candidate nominationTiming“during 2017” (stated in Q1-2017 milestones) “goal… in the first quarter of 2018” Lowered/slipped
LADR: first IND filing2018Not specified previously“goal… file… IND for clinical trials in 2018” Initiated timeline
Aldoxorubicin NDA responsibilityn/aCytRx intended Q4’17 rolling NDA filing plan Responsibility shifts to NantCell; CytRx to support transition Responsibility transferred
Financial guidanceFY17NoneNone providedNo change

Earnings Call Themes & Trends

(No Q3’17 earnings call transcript was available; themes reflect company press releases.)

TopicPrevious Mentions (Q1, Q2 2017)Current Period (Q3 2017)Trend
Aldoxorubicin regulatory/commercial pathQ1: FDA 505(b)(2) path; rolling NDA plan for Q4’17 Licensed to NantCell; NDA ownership and future combo INDs with immunotherapies; CytRx transitions studies From internal plan to partner‑led execution
LADR platform focusQ1: plan to select first ultra‑high‑potency conjugate in 2017 >75 conjugates tested; four leads; nomination targeted Q1’18; IND(s) in 2018 Broader disclosure; timeline refined
Operating model/costsn/a in Q1; Q2 noted loan amendment and cost reduction trajectory Strategic realignment; outsource dev/reg to Hurley to “streamline fixed expenses” Leaner OpEx structure
Capital structure / listingQ2: financings and loan amendments 1‑for‑6 reverse split to support Nasdaq compliance; ~27.6M shares outstanding post‑split Support for listing and flexibility
Debt/interest burdenQ2 interest expense $(0.85)M; loan amendments $10M loan payments in Q3; interest expense $(0.83)M Deleveraging underway

Management Commentary

  • “The third quarter of 2017 was transformative for CytRx,” citing the aldoxorubicin license to NantCell and refocus on LADR .
  • “NantCell… received exclusive rights to develop and commercialize aldoxorubicin for all indications,” with CytRx eligible for up to $343M in milestones and royalties .
  • “To date in 2017… tested over 75… drug conjugates, and four lead candidates have been selected… goal is to nominate the next LADR candidate for clinical development in the first quarter of 2018… file the first LADR‑discovered… IND for clinical trials in 2018” .
  • “This expanded relationship [with Hurley Consulting] will streamline fixed expenses and provide flexibility to access functional level expertise” .

Q&A Highlights

No Q3 2017 earnings call transcript was available for LADX; no Q&A to report [ListDocuments showed no earnings‑call‑transcript for the period].

Estimates Context

  • We attempted to retrieve Wall Street consensus estimates (EPS, revenue) from S&P Global; data were unavailable for this period/ticker via our interface, so no comparison vs consensus is provided. This suggests limited or no active sell‑side coverage at the time. (S&P Global access attempt failed.)

Key Takeaways for Investors

  • Structural pivot de‑risks near‑term cash burn and creates upside optionality: aldoxorubicin moved to a well‑funded partner (NantCell) with milestones/royalties potential; CytRx focuses capital on LADR discovery .
  • Clear cost trajectory: R&D fell ~47% YoY and operating loss narrowed; outsourcing development/regulatory should further temper fixed costs .
  • Balance sheet affords execution runway but warrants monitoring: $46.0M cash, $6.9M deferred revenue, ongoing debt service; $10M term‑loan repayment in Q3 indicates deleveraging progress .
  • Pipeline catalysts in 2018 shift to LADR: candidate nomination (Q1’18 target) and IND(s) in 2018 could re‑rate the platform if preclinical data translate clinically .
  • Stock structure and listing support actions completed (1‑for‑6 reverse split); reduces share count and supports Nasdaq compliance, possibly improving institutional investability .
  • Risk balance: pre‑commercial profile, partner execution risk on aldoxorubicin, and reliance on milestone/royalty economics remain; however, P&L volatility from warrant revaluation can sway EPS near‑term .

Sources: Q3 2017 earnings 8‑K press release and financials ; Q2 2017 earnings 8‑K ; Q1 2017 earnings 8‑K ; strategic realignment press release (Hurley Consulting) ; NantCell license 8‑K –.